Our History
Making a better world with innovative data-driven drug discovery and development.
2022
Growth Stage
- Selected as Presenting Company in Bio Europe 2022
- Selected as Presenting Company in Bio USA 2022
- 2 Patents submitted: Composition of matter
- Signed a joint R&D agreement with ADDI in UK
- Launched an innovative machine learning & wet lab workflow drug discovery platform, Sapientia
- Set up a new company name : SapiensBio, Inc.
2021
Research and Evaluation Stage
- Novel Target Identification & Validation
- Patent submitted: Composition of matter
- Participated in Bio USA 2021
- Started fibrosis & Alzheimer’s disease treatment
2019 ~ 2020
Development stage
- Obtained Venture Business and Corporate R&D Institute Certifications
- Invented new AI drug discovery platform, Sapientia
2018
Foundation stage
- Establishment of SapiensBio, Inc.